Impact of Genetic Polymorphisms on the Metabolic Pathway of Vitamin D and Survival in Non-Small Cell Lung Cancer

Overview

Journal Nutrients

Date 2021 Nov 27

PMID 34836039

Citations 14

Authors

Laura Elena Pineda Lancheros

Cristina Perez Ramirez

Almudena Sanchez Martin

Jose Maria Galvez Navas

Fernando Martinez Martinez

Maria Del Carmen Ramirez Tortosa

Alberto Jimenez Morales

Affiliations

Soon will be listed here.

Abstract

Vitamin D has been associated with risk, development, and progression of cancer. However, the genes involved in its metabolism are highly polymorphic, compromising its activity. The aim of this study is to evaluate the association between the gene polymorphisms involved in the metabolic pathway of vitamin D and survival in patients with non-small-cell lung cancer (NSCLC). The study was designed as an observational cohort which included 194 Caucasians patients from southern Spain with NSCLC. Real-time polymerase chain reaction was used to analyze the following polymorphisms: rs4646536, rs3782130, and rs10877012; rs6068816 and rs4809957; rs7041; rs10741657; rs1544410 (BsmI), rs11568820 (Cdx-2), rs2228570 (FokI), rs7975232 (ApaI), and rs731236 (TaqI). Progression-free survival (PFS) and overall survival were assessed. Cox regression showed that rs4646536 was associated with PFS in the general population ( = 0.0233) and in the non-resected NSCLC subgroup ( = 0.0233). In the resected NSCLC subgroup, rs11568820 was associated with OS ( = 0.0129) and rs7041 with PFS ( = 0.0447). In the non-resected NSCLC subgroup, rs6068816 was associated with PFS ( = 0.0048) and OS ( = 0.0089) and rs731236 and rs7975232 were associated with OS ( = 0.0005) and PFS ( = 0.0002), respectively. The other polymorphisms showed no effect on the results. The rs4646536, rs6068816, rs7041, rs11568820, rs731236, and rs7975232 polymorphisms are associated with survival in NSCLC and may have a substantial role as prognostic markers of the disease.

Citing Articles

Bioinformatics-based modeling of lung squamous cell carcinoma prognosis and prediction of immunotherapy response.

Zhang Q, He H, Wei Y, Li G, Shou L Discov Oncol. 2024; 15(1):840.

PMID: 39724502 PMC: 11671455. DOI: 10.1007/s12672-024-01717-3.

Vitamin D metabolism-related single nucleotide polymorphisms in Chronic Obstructive Pulmonary Disease risk.

Rojo-Tolosa S, Pineda-Lancheros L, Fernandez-Alonso A, Marquez-Pete N, Cura Y, Membrive-Jimenez C Front Endocrinol (Lausanne). 2024; 15:1445712.

PMID: 39583968 PMC: 11581940. DOI: 10.3389/fendo.2024.1445712.

Association Between CYP24A1 Polymorphisms and Bladder Cancer Risk in the Chinese Han Population.

Zhang T, Hu B, Xu S, Wang Y, Zhang H, Li X Biochem Genet. 2024; .

PMID: 38642176 DOI: 10.1007/s10528-024-10771-z.

Revealing the association between vitamin D metabolic pathway gene variants and lung cancer risk: a systematic review and meta-analysis.

Elsalahaty M, Sami Alkafaas S, Bashir A, El-Tarabily K, El-Saadony M, Yousef E Front Genet. 2024; 15:1302527.

PMID: 38482381 PMC: 10933101. DOI: 10.3389/fgene.2024.1302527.

Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway as Survival Biomarkers in Colorectal Cancer.

Perez-Duran C, Marquez-Pete N, Galvez-Navas J, Cura Y, Rojo-Tolosa S, Pineda-Lancheros L Cancers (Basel). 2023; 15(16).

PMID: 37627104 PMC: 10452893. DOI: 10.3390/cancers15164077.

References

Latacz M, Snarska J, Kostyra E, Fiedorowicz E, Savelkoul H, Grzybowski R . Single Nucleotide Polymorphisms in 25-Hydroxyvitamin D3 1-Alpha-Hydroxylase ( Gene: The Risk of Malignant Tumors and Other Chronic Diseases. Nutrients. 2020; 12(3). PMC: 7146376. DOI: 10.3390/nu12030801. View

Parise R, Egorin M, Kanterewicz B, Taimi M, Petkovich M, Lew A . CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer. 2006; 119(8):1819-28. DOI: 10.1002/ijc.22058. View

Wu X, Cheng J, Yang K . Vitamin D-Related Gene Polymorphisms, Plasma 25-Hydroxy-Vitamin D, Cigarette Smoke and Non-Small Cell Lung Cancer (NSCLC) Risk. Int J Mol Sci. 2016; 17(10). PMC: 5085630. DOI: 10.3390/ijms17101597. View

Young M, Ihm J, Lozano Y, Wright M, Prechel M . Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother. 1995; 41(1):37-45. PMC: 11037780. DOI: 10.1007/BF01788958. View

Scazzone C, Agnello L, Lo Sasso B, Ragonese P, Bivona G, Realmuto S . Klotho and vitamin D in multiple sclerosis: an Italian study. Arch Med Sci. 2020; 16(4):842-847. PMC: 7286339. DOI: 10.5114/aoms.2019.86969. View

Yokomura K, Suda T, Sasaki S, Inui N, Chida K, Nakamura H . Increased expression of the 25-hydroxyvitamin D(3)-1alpha-hydroxylase gene in alveolar macrophages of patients with lung cancer. J Clin Endocrinol Metab. 2003; 88(12):5704-9. DOI: 10.1210/jc.2003-030537. View

Srinivasan M, Parwani A, Hershberger P, Lenzner D, Weissfeld J . Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J Steroid Biochem Mol Biol. 2010; 123(1-2):30-6. PMC: 3010457. DOI: 10.1016/j.jsbmb.2010.10.002. View

Higashimoto Y, Ohata M, Nishio K, Iwamoto Y, Fujimoto H, Uetani K . 1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res. 1996; 16(5A):2653-9. View

Auton A, Brooks L, Durbin R, Garrison E, Kang H, Korbel J . A global reference for human genetic variation. Nature. 2015; 526(7571):68-74. PMC: 4750478. DOI: 10.1038/nature15393. View

10.

Scazzone C, Agnello L, Ragonese P, Lo Sasso B, Bellia C, Bivona G . Association of CYP2R1 rs10766197 with MS risk and disease progression. J Neurosci Res. 2017; 96(2):297-304. DOI: 10.1002/jnr.24133. View

11.

Ettinger D, Wood D, Aggarwal C, Aisner D, Akerley W, Bauman J . NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019; 17(12):1464-1472. DOI: 10.6004/jnccn.2019.0059. View

12.

Kong J, Chen X, Wang J, Li J, Xu F, Gao S . Genetic Polymorphisms in the Vitamin D Pathway and Non-small Cell Lung Cancer Survival. Pathol Oncol Res. 2019; 26(3):1709-1715. PMC: 7297819. DOI: 10.1007/s12253-019-00702-4. View

13.

Duan L, Xue Z, Ji H, Zhang D, Wang Y . Effects of CYP2R1 gene variants on vitamin D levels and status: A systematic review and meta-analysis. Gene. 2018; 678:361-369. DOI: 10.1016/j.gene.2018.08.056. View

14.

Kim S, Chen G, King A, Jeon C, Christensen P, Zhao L . Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer. 2012; 77(2):265-71. PMC: 3396768. DOI: 10.1016/j.lungcan.2012.04.010. View

15.

Turna A, Pekcolaklar A, Metin M, Yaylim I, Gurses A . The effect of season of operation on the survival of patients with resected non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2011; 14(2):151-5. PMC: 3279971. DOI: 10.1093/icvts/ivr063. View

16.

Ge N, Chu X, Xuan Y, Ren D, Wang Y, Ma K . Associations between abnormal vitamin D metabolism pathway function and non-small cell lung cancer. Oncol Lett. 2017; 14(6):7538-7544. PMC: 5727627. DOI: 10.3892/ol.2017.7162. View

17.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

18.

Yu W, Ma Y, Flynn G, Muindi J, Kong R, Trump D . Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle. 2010; 9(15):3022-9. PMC: 3040927. DOI: 10.4161/cc.9.15.12381. View

19.

Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L . Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2013; 14(4):433-9. DOI: 10.1016/j.cllc.2013.01.004. View

20.

Asselain B, Barriere J, Clarot C, Vabre J, Gentil Le Pecq B, Duval Y . Metastatic NSCLC: Clinical, molecular, and therapeutic factors associated with long-term survival. Respir Med Res. 2019; 76:38-44. DOI: 10.1016/j.resmer.2019.07.001. View